LITERATURE

1. Alfimov P.V., Kostyukova E.G., Mosolov S.M. Modern methods of overcoming therapeutic resistance in recurrent depression // Biological methods of therapy of mental disorders (evidence-based medicine - clinical practice) / Edited by S.M. Mosolov - Moscow: Sotsial'no-politicheskaya dumka, pp. 438-473.
2. Biological methods of therapy of mental disorders (evidence-based medicine - clinical practice) / Edited by S.N. Mosolov. - Moscow: Sotsial'no-politicheskaya dumka, 2012. - P. 285-286.
3. Kuchmenko D.M., Kozlovsky V.L. Pharmacodynamics of ketamine as a property of an atypical antidepressant (review) // Bekhterev Review of Psychiatry and Medical Psychology - 2013 - No. 4 - P. 20-25.
4. Kuchmenko D.M., Kozlovsky V.L. Ketamine - an atypical antidepressant or a medication-assisted psychotropic therapy? // Bekhterev Review of Psychiatry and Medical Psychology - 2014 - No. 1 - P. 3-9.

5. Mazo GE, Neznanov NG [Therapeutically resistant depression],
6. – 448 с.
7. Mosolov S.M. Clinical application of modern antidepressants. - St. Petersburg: Medical Information Agency, 1995. - P. 21-28.
8. Mosolov S.M. Modern biological hypotheses of recurrent depression (review) // Korsakov Journal of Neurology and Psychiatry - 2012 - Vol. 112, No. 11-2 - P. 29-40.

8. Aan het Rot M., Collins K.A., Murrough J.W., Perez A.M., Reich D.L., Charney D.S. et al. Safety and efficacy of repeated intravenous ketamine administration for the treatment of persistent DeC pressure // Biol - 2010. - Issue 67. - P. 139-145.
9. Aan het Rot, Zarate C.A. Jr. Ketamine for depression: where do we go from here?" // Biol Psychiatry. - 2012. - Issue 72. - P. 537-547.

10. Autry E., Adachi M., Nosyreva E., Na E.S., Los M.F., Cheng P.F. et. al. Resting NMDA receptor blockade induces rapid behavioral response to antidepressants // Nature. - 2011. - Issue 475. - С. 91-95.
11. Berman M., Cappiello A., Anand A., Oren DA, Heninger GR, Charney DS et al. Antidepressant effect of ketamine in patients with depression // Biol Psychiatry. - 2000. - Vol. 47. - P. 351-354.
12. Beurel, Song L., Jope R.S. Inhibition of glycogen synthase kinase C3 is required for the rapid antidepressant effect of ketamine in mice // Mol Psychiatry. - 2011. - Vol. 26. - P. 1068-1070.
13. Bjerre, Fontenay C. Ketamine in Melancholic Depression // Ugeskr Lager. - 2010. - Issue 172. - P. 460-461.

14. Bloch M.H., Wasylink S., LanderosCWeisenberger A., Panza K.E., Billingslea E., Leckman J.F. et al. Effects of ketamine in the treatment of refractory obsessive-compulsive disorder // Biol - 2012. - Issue 72. - P. 964-970.
15. Carr B., Goudas L.C., Denman W.T., Brookoff D., Staats P.S., Brennen L. et al. Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled crossover study // Pain - 2004. - Issue 108. - P. 17-27.
16. Correll E., Futter G.E. Two examples of patients with major depressive disorder treated with low doses (subanesthesia) of ketamine // Pain Med. - 2006. - Issue 7. - P. 92-95.

17. Denk M.C., Rewerts C., Holsboer F., ErhardtCLehmann A., Turck C.W. Monitoring the response to ketamine treatment in a depressed patient through the peripheral target of RapamyC cin activation in mammals // Am J - 2011. - Vol. 68. - P. 751-752.
18. DeWilde E, Levitch KF, Merro JW, et al. The promise of ketamine for the treatment of resistant depression: current evidence and future directions // Ann NY Acad Sci. 2015 - Vol. 1345 - pp. 47-58.
19. Diamond R et al. Ketamine infusions for treatment-resistant depression: a series of patients treated weekly or twice weekly in an ECT clinic // J PsychopharmacolC ogy. - April 2014.
20. DiazGranados, Ibrahim L., Brutsche N.E., Newberg A., Kronstein P., Khalife S., et al. Randomized additional study of the antagonist NCmethylCDCaspartate in the treatment of crisis bipolar depression // Arch Gen Psychiatry. - 2010. - Issue 67. - P. 793-802.
21. DiazGranados N., Ibrahim L.A., Brutsche N.E., Ameli R., Henter I.D., Luckenbaugh D.A. et al. Rapid resolution of suicidal ideation after a single infusion of the NCmethylCDCaspartate antagonist in patients with treatment-resistant major depressive disorder // J Clin PsyC chiatry. - 2010. - Vol. 71. - P. 1605-1611.
22. Fonda et al. Ketamine administration for depressive disorders: a systematic review and meta-analysis // J Psychopharmacology. - July 2014.

23. Glue, Gulati A., Le Nedelec M., Duffull S. DoseC and ExposureResponse to Ketamine in Depression // Biol Psychiatry. - 2011. - Issue 70. - P. 9-12.
24. Goforth H.W., Holsinger T. Rapid relief of severe major depressive disorder with preoperative ketamine and electroconvulsive therapy // J - 2007. - Vol. 23. - P. 23-25.
25. Ibrahim, DiazGranados N., FrancoCChaves J., Brutsche N., Henter I.D., Kronstein P. et al.
26. The course of improvement of depression symptoms after a single intravenous infusion of ketamine versus AddCon Riluzole: results of a 4-week, double-blind, placebo-controlled study // Neuropsychopharmacology. - 2012. - Issue 37. - P. 1526-1533.
27. Kavalali T., Monteggia L.M. How ketamine induces the rapid antidepressant ReC

The answer?" // Curr Opin Pharmacol. - 2015. - Issue 20. - P. 35-39.

28. Kranaster L., KammererCCiernioch J., Hoyer C., Sartorius A. Clinically beneficial effects of ketamine as an anesthetic for electroconvulsive therapy: a retrospective study // Eur Arch Psychiatry Clin - 2011 - Vol. 261. - P. 575-582.
29. Krystal D, Weiner RD, Dean MD, Lindahl VH, Tramontozzi LA 3rd, Falcone G et al.

Comparison of seizure duration, ictal EEG and cognitive effects of hexital anesthesia with ketamine and MethoC with ECT // J Neuropsychiatry Clin Neurosci. - 2003. - Issue 15. - P. 27-34.

30. Lally, Nugent AK, Lackenbaugh DA, et al. Neural correlates of changes in major depression

Severe anhedonia after OpenClabel ketamine // J Psychopharmacol. - 2015. - Vol. 29. - P. 596-607.

31. Lee, Syeda K., Maruschak N.A. et al. A new look at the antisuicidal effect

with ketamine treatment: precognitive effect // J Clin Psychopharmacol. - 2016. - Issue 36. - P. 50-56.

32. Loo C., Sainsbury, Martin D., MacPherson R. Synergistic antidepressant effects with

Ketamine and ECT // J ECT. - 2009. - Issue 25. - P. 150.

33. Maeng, Zarate C.A. Jr., Du J., Schloesser R.J., McCammon J., Chen G. et. al. Cellular mechanisms underlying the antidepressant effects of ketamine: the role of alpha-caminoC-3C-hydroxy-C5C-methylisoxazole-C4C-propionic acid receptors // Biol Psychiatry. - 2008. - Issue 63. - P. 349-352.
34. Matthew J., Merro J.W., Anhett Roth M., Collins K.A., Reich D.L., Charney D.S. Riluzol

for the prevention of relapse after intravenous ketamine in the treatment of persistent depression: a pilot randomized placebo-controlled extension study // Int J NeuropsychopharmaC col. - 2010. - Issue 13. - P. 71-82.

35. Montgomery A, Asberg M. A new depression scale designed to be sensitive to

Change // Br J Psychiatry. - 1979. - Issue 134. - P. 382-389.

36. Morgan J.A., Mutzelfeldt L., Curran H.W. Effects of chronic ketamine self-monitoring on neurocognitive function and psychological well-being: A 1-year longitudinal study // Addiction. - 2010. - Vol. 105. - P. 121-133.
37. Moukaddam N.J., Hirschfeld R.M.A. Intravenous antidepressants: A review // Depression.

Trigger. - 2004. - Issue 19. - P. 1-9.

38. Murrough W., Collins K.A., Fields J. et al. Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder // Transl Psychiatry. - 2015. - Issue 5. - P. 509.
39. Murrough W., Gallo J.M., Collins K.A., Aan het Rot M., Charney D.S. Response: DoseC and

Reaction to the effect of ketamine in depression // Biological Psychiatry. - 2010. - Issue 70. - P. 11-12.

40. Murrough J.W., Perez A.M., Mathew S.J., Charney D.S. A case of sustained remission

After an acute course of ketamine in the treatment of persistent depression // J Clin PsyC chiatry. - 2011. - Issue 72. - P. 414-415.

41. Murrough W., Perez A.M., Pillemer S. et al. Rapid and long-lasting antidepressant EfC

Effects of repeated ketamine infusions in the treatment of persistent major depression // Biol Psychiatry. - 2012 July 26.

42. Neir, Singh Ajit S. The role of the glutamatergic system in posttraumatic stress disorderC

der // CNS Spectr. - 2008. - Vol. 13, No. 7. - P. 585-591.

43. Newcomer J.W., Farber N.B., JevtovicCTodorovic V., Selke G., Melson A.K., Hershey T. et al. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis // - 1999. - Issue 20. - P. 106-118.
44. Okamoto, Nakai T., Sakamoto K., Nagafusa Y., Higuchi T., Nishikawa T. Rapid AntideC

Pressor effect of ketamine anesthesia during electroconvulsive therapy of resistant depression: comparison of ketamine and propofol anesthesia // J ECT. - 2010. - Issue 26. - P. 223-227.

45. Parides K. et al. Efficacy of intravenous ketamine for the treatment of chronic post-traumatic stress disorder

matic Stress Disorder a Randomized Clinical Trial // Jama Psychiatry. - April 2014.

46. Paul, Schaaff N., Padberg F., Moller H.J., Frodl T. Comparison of Racemic Ketamine and Sketamine in TreatmentCresistant Major Depression: Report of Two Cases // World J Biol Psychiatry. - 2009. - Vol. 10. - P. 241-244.
47. Phelps E, Brutsche N, Moral JR, Lackenbaugh DA, Manji HK, Zarate CA. The family of Jr.

History of alcohol dependence and initial antidepressant response to the aspartate antagonist NCmethylCDC // Biol Psychiatry. - 2009. - Issue 65. - P. 181-184.

48. Pilc, Wieronska J.M., Skolnick P. Glutamate-based antidepressants: preclinical psychology

Pharmacology // Biol Psychiatry - 2013. - Issue 73. - P. 1125-1132.

49. Price B., Nock M.K., Charney D.S., Matthew S.J. The effect of intravenous ketamine on explicit and implicit suicidality indicators during treatment of resistant depression // Biol PsychiaC try. - 2009. - Vol. 66, No. 5. - P. 522-526.
50. Riaza Bermudo-Soriano, Perez-Cródriguez MM, Vaquero-Clorenzo C, Baca-Charcia E.

New perspectives on glutamate and anxiety // Pharmacol Biochem Behav. - 2012. - Vol. 100, No. 4. - P. 752-774.

51. Rodriguez L., Kegeles L.S., Flood P., Simpson H.B. Rapid resolution of obsessions after

Infusion of intravenous ketamine in a patient with treatment-resistant obsessive-compulsive disorder // J Clin Psychiatry. - 2011. - Issue 72. - P. 567-569.

52. Rodriguez C.L., Kegeles L.S. et. al. Randomized controlled crossover study of ketamine

in ObsessiveCcompulsive Disorder: ProofCofCconcept // Neuropsychopharmacology. - 2013. - Issue 38. - P. 2475-2483.

53. Sanacora, Kendell SF, Levin Y, Cement AA, Fenton LR, Coric V et al.

Evidence for the effectiveness of riluzole in patients with residual symptoms of depression taking antidepressants // Biol Psychiatry. 2007. - Issue 61. - P. 822-825.

54. Steroux, L., Shermat, R., Thierry, Simon P. Tail suspension test: a new method for

Screening of antidepressants in mice // Psychopharmacology (Berl). - 1985. - Issue 85. - P. 367-370.

55. Trullas R., Skolnick P. Functional Antagonists at the NMDA Receptor Complex Exhibit Antidepressant Actions // Eur J Pharmacol. - 1990. - Issue 185. - P. 1-10.

56. Valentin GW, Mason GF, Gomez R, Fasula M, Vacl J, Pitman B, et al. The antidepressant effect of ketamine is not associated with changes in amino acid neurotransmitter content in the occiput as measured by [(1)H]CMRS // Psychiatry Res NeuroimagC ing.
57. Zarate A. Jr., Singh J. B., Carlson P. J., Brutsche NE, Amelie R., Lackenbaugh DA, et al.

A randomized trial of the NCmethylCDCaspartate antagonist in the treatment of persistent major depression // Arch Gen Psychiatry. - 2006. - Issue 63. - P. 856-864.

58. Zarate A. Jr., Brutsche N.E., Ibrahim L. et al. Replication of the efficacy of ketamine antidepressants in bipolar depression: the AddCon randomized controlled trial // Biol Psychiatry. - 2012.-Vol. 71, No. 11. - P. 939-946.
59. Zarate A. Jr, Payne J. L., Quiroz J., Sporn J., Denikoff K. K., Lackenbaugh D., et al. An

OpenClabel Trial of Riluzole in Patients with Treatment-Resistant Major Depression // Am J Psychiatry. - 2004. - Issue 161. - P. 171-174.

60. Sarate A. Jr., Quiroz J.A., Singh J.B., Denikoff K.D., De Jesus G., Lakenbaugh D.A. et al. An open-label trial of the glutamate modulator riluzole in combination with lithium for the treatment of bipolar depression // Biol Psychiatry. - 2005. - Vol. 57. - P. 430-432.

Source.

The Kyiv Expio Center is the first and only medical institution to provide ketamine therapy in Ukraine.